-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

Benzinga·04/13/2026 12:21:09
Listen to the news
Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $145.